Citation Impact
Citing Papers
Removing T-cell epitopes with computational protein design
2014 StandoutNobel
Modulation of immune cell reactivity with cis -binding Siglec agonists
2021 StandoutNobel
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
2009 StandoutScience
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
2016
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
2006 StandoutNature
Inhibition of the G2 DNA Damage Checkpoint and of Protein Kinases Chk1 and Chk2 by the Marine Sponge Alkaloid Debromohymenialdisine
2001
Bioluminescent imaging of Cdk2 inhibition in vivo
2004 StandoutNobel
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
2005 StandoutNobel
Estrogen receptors and human disease
2006 Standout
Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer
2001
Selective inhibition of bleomycin-induced G2 cell cycle checkpoint by simaomicin α
2004 StandoutNobel
Role of estrogens in development of prostate cancer
2004
Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
1998
Cell-cycle checkpoints and cancer
2004 StandoutNature
mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery
2002 Standout
Monoclonal antibody therapy for B cell non-Hodgkin’s lymphomas: emerging concepts of a tumour-targeted strategy
1999
Anaplastic lymphoma kinase proteins in growth control and cancer
2004
Cancer Statistics, 2006
2006 Standout
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
2007 StandoutNature
The antiandrogen withdrawal syndrome
1997
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies
2004
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor
2010 Standout
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
2002 Standout
The Epigenomics of Cancer
2007 Standout
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007 Standout
Mammalian display screening of diverse cystine-dense peptides for difficult to drug targets
2017 StandoutNobel
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 Standout
Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites
2021 StandoutNobel
3-Hydroxychromones as cyclin-dependent kinase inhibitors: Synthesis and biological evaluation
2006
Phase II Trial of Toremifene in Androgen-Independent Prostate Cancer
2001
Structural features underlying selective inhibition of protein kinase CK2 by ATP site‐directed tetrabromo‐2‐benzotriazole
2001
Identification and expansion of human colon-cancer-initiating cells
2006 StandoutNature
Selectivity of 4,5,6,7‐tetrabromobenzotriazole, an ATP site‐directed inhibitor of protein kinase CK2 (‘casein kinase‐2’)
2001
CD22 as a target of passive immunotherapy
2003
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
2000
Inflammation and cancer: back to Virchow?
2001 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
2010
Competition and Compensation
2002 Standout
The CDK inhibitors in cancer research and therapy
2011
Synthesis of 1,7-annulated indoles and their applications in the studies of cyclin dependent kinase inhibitors
2004
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
2004 Standout
Ligand-targeted therapeutics in anticancer therapy
2002
Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells
2009
Current strategies in the management of hormone refractory prostate cancer
2003
AKT/PKB Signaling: Navigating the Network
2017 Standout
Role of alpha1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL+ Leukemic Cells to the Abl Inhibitor STI571
2000
The molecular basis and potential role of survivin in cancer diagnosis and therapy
2001
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
2006 Standout
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia
2004
Cyclin-dependent kinases as new targets for the prevention and treatment of cancer
2002
Ras, PI(3)K and mTOR signalling controls tumour cell growth
2006 StandoutNature
Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation
2013 StandoutNature
Targeting the checkpoint kinases: chemosensitization versus chemoprotection
2004
Sirolimus for Kaposi's Sarcoma in Renal-Transplant Recipients
2005 Standout
Octreotide in the Management of Hormone-Refractory Prostate Cancer
2001
Head and Neck Cancer
2001 Standout
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
Synthesis of bisindolylmaleimides related to GF109203x and their efficient conversion to the bioactive indolocarbazoles
2006
Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors
2000
Copper-Mediated Coupling Reactions and Their Applications in Natural Products and Designed Biomolecules Synthesis
2008 Standout
The kinase Grk2 regulates Nedd4/Nedd4-2-dependent control of epithelial Na + channels
2004 StandoutNobel
A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.
2002
Synthesis, Structure−Activity Relationship, and Biological Studies of Indolocarbazoles as Potent Cyclin D1-CDK4 Inhibitors
2003
Mechanism and Management of AKT Inhibitor-Induced Hyperglycemia
2008
Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate Cancer
1999
Memory--a Century of Consolidation
2000 StandoutScience
Synthetic Approaches to Indolo[6,7-a]pyrrolo[3,4-c]carbazoles: Potent Cyclin D1/CDK4 Inhibitors
2004
Cyclin-dependent kinases regulate lysosomal degradation of hypoxia-inducible factor 1α to promote cell-cycle progression
2014 StandoutNobel
Thermal ablation of tumor cells with antibody-functionalized single-walled carbon nanotubes
2008
The Sonogashira Reaction: A Booming Methodology in Synthetic Organic Chemistry
2007 Standout
STEROID HORMONE WITHDRAWAL SYNDROMES
1997
Immunogenicity of therapeutic recombinant immunotoxins
2016
Occurrence, Biogenesis, and Synthesis of Biologically Active Carbazole Alkaloids
2012 Standout
Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.
2011
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
2009
Aryl−Aryl Bond Formation by Transition-Metal-Catalyzed Direct Arylation
2007 Standout
DEXAMETHASONE DOES NOT SIGNIFICANTLY CONTRIBUTE TO THE RESPONSE RATE OF DOCETAXEL AND ESTRAMUSTINE IN ANDROGEN INDEPENDENT PROSTATE CANCER
2000
Synthesis of N-alkyl substituted bioactive indolocarbazoles related to Gö6976
2006
Drug Discovery: A Historical Perspective
2000 StandoutScience
Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates
2011
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
1997
Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes.
1999
The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition
2014 Standout
Frequent loss of estrogen receptor-beta expression in prostate cancer.
2001
First Total Synthesis of Naturally Occurring (−)‐Nitidon and Its Enantiomer
2004
The protein kinase C inhibitor Gö6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints.
2003
Structure-Based Generation of a New Class of Potent Cdk4 Inhibitors: Newde NovoDesign Strategy and Library Design
2001
Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway
2006
Aromatic Trifluoromethylation with Metal Complexes
2011 Standout
The Halogen Bond
2016 Standout
Synthesis and Histone Deacetylase Inhibitory Activity of Largazole Analogs: Alteration of the Zinc-Binding Domain and Macrocyclic Scaffold
2009
Expression of BCL-2 Oncoprotein and P53 Protein Accumulation in Bone Marrow Metastases of Androgen Independent Prostate Cancer
1997
Anaplastic lymphoma kinase: signalling in development and disease
2009
Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor
2004
Flutamide Versus Prednisone in Patients With Prostate Cancer Symptomatically Progressing After Androgen-Ablative Therapy: A Phase III Study of the European Organization for Research and Treatment of Cancer Genitourinary Group
2001
Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.
2002
Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection
2010
Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes
2014 StandoutNobel
Works of Donna Headlee being referenced
A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer
1995
Disposition of Phenylbutyrate and its Metabolites, Phenylacetate and Phenylacetylglutamine
1995
Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables
1995
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
1998
Clinical pharmacology of UCN-01: Initial observations and comparison to preclinical models
1998
Cyclin-Dependent KinasesInitial Approaches to Exploit a Novel Therapeutic Target
1999
Phase I study of phenylacetate administered twice daily to patients with cancer
1995
Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study
1995
A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer.
1999
Surprising Activity of Flutamide Withdrawal, When Combined With Aminoglutethimide, in Treatment of "Hormone-Refractory" Prostate Cancer
1994
Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma
2005
A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma
1996
Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms
2001
A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer.
1994
Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.
1998
Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered as a Daily 1-Hour Infusion in Patients With Advanced Neoplasms
2002
Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6.
2003
A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
2000